Breast cancer prevention practices vary across CanadaAugust 15, 2007Breast cancer preventive practices for Canadian women carrying the cancer gene vary across the country, says University of Toronto research, and many women are not taking advantage of the options available. The study, published in the journal Open Medicine, followed the experiences of Canadian women with a BRCA1 or BRCA2 mutation - a genetic mutation that predisposes them to a 87 per cent lifetime risk of developing breast cancer. Women carrying the gene have several options for cancer prevention including prophylactic surgery, chemoprevention and screening; however, researchers observed significant differences across Canada in the uptake of these preventions, with women in Quebec the least likely to use preventive measures. "We were very surprised by the discrepancy in preventative measures taken across the country," says Professor Kelly Metcalfe, Lawrence Bloomberg Faculty of Nursing, lead author of the study. "The benefit of genetic testing is that we can identify women at high risk of developing breast cancer and hopefully reduce that risk. Ultimately though, women have to elect to undertake one of the options." In the study, 672 Canadian women were identified as carrying the genetic mutation. Followup questionnaires were completed after a mean of four years. Out of the 342 women without breast cancer after four years, 157 (46 per cent) had not undertaken any cancer prevention option such as a mastectomy, oophorectomy or tamoxifen or raloxifene - drugs used in chemoprevention. Broken down geographically, 39 per cent of women with the genetic mutation in Ontario did not take preventive measures; 34 per cent in Western Canada and 62 per cent in Quebec. "The numbers show a huge discrepancy, with women in Quebec being the least likely to elect for a preventive option," Metcalfe says. "This will have significant implications in terms of the numbers of cancers we see developing in this high-risk group. We still need to do more research to explain why these differences exist." University of Toronto |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||